Waystar (WAY) Q2 2026 earnings review
Guidance Raised, But Underlying Revenue Quality is Splitting
Waystar delivered a solid Q2 2026 beat and raised full-year guidance across the board. However, the top-line narrative masks a sharp divergence beneath the hood. The core software engine (Provider/Subscription) is thriving with 34% YoY growth, heavily aided by the Iodine acquisition integration. Conversely, legacy Volume-Based revenue growth collapsed to 3% as macroeconomic headwinds and a shift to digital statements weigh on patient payments. More alarmingly, Net Revenue Retention (NRR) slid to 108%, a steep drop from 115% a year ago, as tailwinds from a competitor's 2024 cyber event fully wash out. Despite these growth crosscurrents, Waystar's profitability remains an impenetrable fortress at a 43% Adjusted EBITDA margin.
🐂 Bull Case
Adjusted EBITDA margin held pristine at 43%. Management is successfully rotating out of low-margin volume business into highly profitable enterprise platform subscriptions.
The number of clients generating over $100,000 in LTM revenue grew 15% YoY to 1,453. Larger clients are standardizing on Waystar's platform.
🐻 Bear Case
Net Revenue Retention has steadily decelerated for five consecutive quarters (115% down to 108%). The easy cross-sell momentum and competitor disruption tailwinds are fading.
Volume-based revenue grew just 3% YoY, down from 14% a year ago. The shift to digital patient statements is structurally pressuring top-line unit economics.
⚖️ Verdict: ⚪
Neutral. The guidance raise and impenetrable margins support the 'Rule of 50' narrative, but a 108% NRR and the collapse in volume-based growth contradict the story of uninhibited platform expansion. Growth quality is becoming lopsided.
Key Themes
Subscription Engine Powering the Top Line
Waystar's Subscription revenue remains the primary growth engine, up 34% YoY to $176.3M (decelerating slightly from 38% in Q1). Provider-specific revenue jumped 23%. This validates the strategic pivot toward end-to-end platform consolidation and the successful cross-sell integration of the Iodine Software acquisition.
Volume-Based Revenue Hits a Wall
Decelerating aggressively. Volume-based revenue grew a meager 3% YoY (to $142.1M), a steep drop from the 14% growth seen a year ago. Patient revenue was up only 7%. Management previously cited macro headwinds—specifically healthcare coverage changes and an accelerated, structural shift from print to digital patient statements. While neutral to margin dollars, this permanently suppresses top-line unit economics.
NRR Floor Remains Elusive
Decelerating. Net Revenue Retention dropped to 108%, a severe contraction from 115% in Q2 FY25. This contradicts the company's aggressive narrative of frictionless platform upselling. As the massive wave of business captured during a competitor's 2024 cyber event fully annualizes, organic expansion within the base is visibly cooling.
Large Enterprise Cohort Expanding
Accelerating slightly vs expectations. Clients generating >$100,000 in LTM revenue hit 1,453, up 15% YoY (compared to 14% growth in the prior year). Waystar's strategy to displace fragmented point solutions with a unified RCM platform is winning larger, stickier health system contracts.
AltitudeAI and Product Innovation
Waystar is heavily leveraging its AltitudeAI suite to defend its moat against 'lightweight' AI upstarts and EHR vendors. Recent launches, including a recoupment solution (reducing reconciliation time by 80%) and pre-bill anomaly detection, are moving the company beyond basic clearinghouse functions into high-ROI, monetizable AI SKUs.
Implementation Lag on Large Deals
While large enterprise bookings are reportedly at record highs, management has continually cautioned that these complex platform deals carry an implementation lag of 6 to 18 months. This creates a structural delay between reported bookings success and actual revenue recognition, which may be contributing to the slowing overall revenue growth rate.
Other KPIs
Stable. The 43% margin is perfectly flat compared to Q1 2026 (43.1%) and up from 41.6% a year ago. The mix shift toward higher-margin subscription software is successfully offsetting the volume-based revenue headwinds.
Represents solid cash generation, though it reflects the capital intensity of capitalized software and recent integration efforts. Cash flow from operations came in at $59.4 million.
Guidance
Accelerating slightly. The midpoint ($1.285B) implies roughly 17% YoY growth vs FY25's $1.099B. Management raised the bottom end of the prior guidance range by $2 million, signaling confidence despite the volume-based headwinds.
Accelerating. The midpoint of $540M was raised by $5 million from the prior quarter's guide. This implies an annual margin of roughly 42%, up nicely from the $462M delivered in FY25, validating the realization of post-Iodine cost synergies.
Accelerating. Raised from the previous range of $317M - $335M. This flows down to a raised diluted non-GAAP EPS guide of $1.61 - $1.70, rewarding investors for the favorable margin mix.
Key Questions
NRR Stabilization Floor
Net Revenue Retention has contracted 700 bps over the last year to 108%. With the competitor cyber-event tailwinds fully washed out, where is the structural floor for NRR, and what specific cross-sell motions will re-accelerate it?
Volume-Based Headwinds Timeline
Volume-based revenue growth has decelerated to 3%. How much of this is driven by the structural shift from print to digital patient statements, and when do you expect this specific headwind to fully annualize?
Large Deal Revenue Conversion
Given the 6 to 18-month implementation lag for large enterprise deals, what proportion of the record bookings cited in late FY25 are currently contributing to the Q2 revenue run-rate, and how steep is the ramp expected in H2?